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Ticlopidine Administration After Stent Placement: Frequency of Adverse
Reactions
R.J. Russo, K.M. Stevens, S.L. Norman, D.A. Cloutier, P.S.Teirstein.
Scrfpps Clinic, La Jolla, CA, USA
During a 13-month period (Januaty 1995 to January 1996), 682 patients un-
denvent Palmaz-Schatz coronary stent placement at Scripps Clinic and were
discharged on a variety of anticoagulation protocols, all of which included
ticlopidine (500 mg/day) for 1 month. Discharge medications were: Ticlid (T)
+ aspirin (ASA) 325 mg/day in 385 (56.5%) pts; T + ASA + enoxaparin (E)
60 mg/day in 228 (33.4%) pts; T + ASA + waffarin (W) in 93 (13.6%) pts;
and T + ASA + E + W in 18 (2.6%) pts. Patients were examined within 1
week of hospital discharge, a complete bled cell count was obtained at 2
weeks, and telephone follow-up was obtained at 1 month. Results: Adverse
effects were experienced by 29 (4.257.) pts during the 1 month of ticlopi-
dine administration and included rash in 13 (1.91%) pts, gastrointestinal (Gl)
distress in 6 (1.17%) pts, neutropenia (absolute neutrophil count [ANC] <
1500) in 5 (0.73%) pts, hives in 2 (0.29%) pts, and GI bleeding in 1 (0.15%)
pt. In 12 (1.76%) pts who experienced an adverse effect, ticlopidine was
tolerated for a full month after a reduction of dose to 250 mgfday. However,
17 (2.49%) pts required discontinuation of ticlopidine prior to 1 month due
to a medication adverse effect. indications for discontinuation were rash in
7 (1.03%) pts, GI distress in 6 (0.68%) pts, neutropenia (ANC < 1000) in
3 (0.44%) pts, and hives in 1 (0.15%) pt. The frequency of adverse effects
was similar for all anticoagulation protocols (T+ ASA, 4.25%; T + ASA + E,
4.0%; T + ASA + W. 2.220A;and T + ASA + E + W, 12.50/-:p = ns). No patient
experienced irreversible neutropenia. Conclusion: Ticlopidine therapy for 1
month after stent placement is associated with a low rate of adverse effects
which require either reduction of dose or discontinuation of medication.
8:45
~771-21 lncidenceOfNeutropeni*atalThr~mb~~W~Penia
Associated With Ona Month of Ticlopidine Therapy
Post Coronary Stenting
G.Szto,S. Lewis, K. Punamiya, S. Jung, R. Landin, M. Ball, Z. Hodes,
D. Lips, J. Coverdala, T. Linnemeier. fVorfhsideCardio/ogx PC, Indiana
Heart lrrstitute, Indianapolis, IN, USA
Objective:The reported incidence of neutropenia (NTP) (absolute neutrophil
count [ANC] -=1200/ml) in patients (pts) on chronic ticlopidine (TIC) therapy
for TIAs is 2.4%. The incidence of NTP orthrombocyfopenia (TCP) with one
month TIC therapy post coronaty stenting has not been reported.
Methods: We prospectively studied complete blood counts (CBC) at 2,4,
and 6weeks on 340 consecutive pts treated with coronary stenting from 4/95
to 6/96. A total of 542 stents (463 Palmez-Schatz, 59 Gianturco-Roubin, 18
Multi-Link, 2 others) were placed in 353 lesions (mean 1.6 stentelpt). Mean
age was 61 * 11 yeara (males 70%). Adjunetive high pressure (>16 ATM)
balloon dilatation was performed in all pts. A total of 98% (333/340) of pts
were released on ASA, 100%.on TIC, with sub-Q heparin used in high risk
subsets.
Resu/ta:Neutropenia was deteeted in 4 pts (1.2%) with severe NTP (ANC
< 450/ml) in 2 of these 4 pts (0.67.). TCP was detected in 2 pts (0.6Yo)with
1 (0.3%) death from cerebral hemorrhage. TIC was discontinued in 4/340
(1.2%) pts before one month because of a reduction in ANC without stent
thrombosis. Subacute stent thrombosis occurred in 3/340 (0.9Yo)pts in the
cohort as a whole.
Conclusion: The incidence of serious NTP is 1.2%, fatal TCP 0.37. of
pts. A drop in ANC necessitating discontinuation of TIC occurred in 1.2%
of pts. Further studies using TIC for shorter duration have been initiated.
Meanwhile, pts receiving TIC for one month should continue to have aerial
monitoring of CBCS.
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Clopidogrel, A Novel Platelet ADP-Raceptor
Antagonist Inhibits Aspirin and
Ticlopidine-Rasistant Stent Thrombosis
R. Makkar, N. Eigler, S. Kaul, H. Zeng, J.-M. Herbert 1, F. Litvack.
Cedars-Sinai Medical Cente< Los Angeles, CA, USA, 1Sanofi Recherche,
Toulouse,France
Background: Combined aspirin (A) and ticlopidine (T) have been shown to
reduce stent thrombosis (ST), However,the efficacy of this approach in small
vessels under high-shear conditions is not known. Methods and Resu/ts:
Pigs (n= 6, wf23 + 2 kg) were pretreated with ticlopidine (T) (250 mg po/d/3
days) and aspirin (A) (10 mg/kg iv). Unpolished nitinol stents (n = 39) were
expandad to 2 mm diameter in a tubular perfusion chamber and interposed
in an ex-vivo porcine arferiovenous shunt. Stents were exposed to flowing
arterial blood at different shear rates (s–l) for 20 minutes. Animals were then
treated with clopidogrel (C) (5 mg/kg iv) and experiments were repeated.
Shear was regulated by altering the blood flow. ST was quantified by mea-
suring drythrombus weight. ADP-induced (2.5 mM) platelet aggregation (PA)
and bleeding time (BT) were estimated before and after C. C reduced PA by
45+ 5% and prolonged BT from 4 + 1 to 12 & 2* minutes (p c 0.01).
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Conclusions: Combined aspirin and ticlopidine do not inhibit acute throm-
bmis under conditions simulating high-risk scenting.Clopidogrel inhibits high-
shear mediated stent thrombosis resistant to aspirin and ticlopidine under
similar conditions.
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Polymer-Coated Stents by Immobilisation of
Plateiat-Targeted Urokinase
R.K. Aggarwal, DC. Ireland, MA. Azrinl, D.P.de Bono, A.H. Gerehlick.
Dapatiment of Cardiology, University of Leicestec UK, 1University of
Connecticut, Farmington, CT, USA
We have previously targeted urokinase (UK) to platelets by chemical con-
jugation with anti rabbit platelet GP llb/llla antibody (AZl) and shown the
enhanced platelet antiaggregatory effects of AZI-UK conjugate compared
with AZ1 antibody alone. This study aimed to evaluate the antithrombotic
properties of AZI-UK immobilised to cellulose polymer-coated stents (n =
22).
Mathods:Antithrombotic effects were determined by implanting the stents
into flow reduced, deeply injured iliac afteriea of New Zealand White tibbits
(n= 11). Each animal had a conjugate-immobilised stent in one vessel (Gr. 1)
and a base polymer control stent in the contrelateral vessel (Gr. H).Arterial
patency was determined after 2 hrs (n = 6 animals, acute group) and 28
days (n = 5 animals, chronic group). For the acute group, blood flow was
measured continuously using perivascular flowprobes (Tranaonice, NY) and
platelet adhesion determined using Ill Iridium Iabelled autologous piatetetS.
Total occlusion was defined as flow <0.5 mllmin for >10 rein; cyclic flow
variation (CFV) as return to flow >0.5 ml/min within 10 min. In the chronic
Gr. Acute group Chronicgroup
aPlatelets bCFV freq: C2 hrflow dn occluded ‘noccluded
(X107) (hr-i) (% baseline)
I 16.7 + 2.2 0 76,2 + 10,3 0 of 6 1 of 5
II 35.4 + 6.7 5.9 + 2.2 16.4 + 0.4 4 of 6 3 of 5
